Literature DB >> 8599435

Dermal cylindroma. An immunohistochemical study of thirteen cases.

O Tellechea1, J P Reis, O Ilheu, A P Baptista.   

Abstract

Thirteen dermal cylindromas (DC) have been studied immunohistochemically using a panel of antibodies that stain different portions of normal eccrine and apocrine glands. Distinct staining patterns were found in the different cell populations of the tumor. Although the expression of cytokeratins (CK) 19 and 1/10/11 in occasional duct structures could indicate excretory (ductal) differentiation, a link between DC and apocrine secretory coil is suggested by the expression of alpha-1-antichymotrypsin, lysozyme, human milk factor globulin 1, alpha smooth muscle actin (1A4), and CK 8 and 18. The presence of intermingled S-100 protein-, HLA DR-, and CD1a-positive cells argues for the existence of Langerhans cells within the neoplasm. DC shares epithelial membrane antigen, carcinoembryonic antigen, mucin-like carcinoma-associated antigen (B12), laminin, collagen IV, fibronectin, and CD34(QBEND/10) expression with both eccrine and apocrine glands.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8599435

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  6 in total

1.  Benign cylindroma: a rare differential diagnosis of external ear canal tumour.

Authors:  David Schwarz; Uta Drebber; Monika Ortmann; Andreas Anagiotos
Journal:  BMJ Case Rep       Date:  2016-01-11

2.  S-100 protein+ dendritic cells and CD34+ dendritic interstitial cells in thyroid lesions.

Authors:  Anna Batistatou; Vassiliki Zolota; Chrisoula D Scopa
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

3.  Solitary cylindroma with malignant transformation.

Authors:  Cherry Bansal; Mayanka Batra; Nirupma Lal; A N Srivastava
Journal:  Indian J Dermatol       Date:  2012-03       Impact factor: 1.494

4.  Malignant cylindroma in a patient with Brooke-Spiegler syndrome.

Authors:  Liliane Borik; Patricia Heller; Monica Shrivastava; Viktoryia Kazlouskaya
Journal:  Dermatol Pract Concept       Date:  2015-04-30

5.  Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.

Authors:  N Rajan; R Elliott; O Clewes; A Mackay; J S Reis-Filho; J Burn; J Langtry; M Sieber-Blum; C J Lord; A Ashworth
Journal:  Oncogene       Date:  2011-05-09       Impact factor: 9.867

6.  The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.

Authors:  Alexandre Regamey; Daniel Hohl; Jia Wei Liu; Thierry Roger; Priit Kogerman; Rune Toftgard; Marcel Huber
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.